Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sbp-101 save search
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 2.03%
H: 0.66%
C: -11.26%
sbp-101 association presentation cancer research
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
Published: 2023-12-04 (Crawled : 13:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: -3.96%
H: 0.0%
C: -9.72%
sbp-101 publication cell
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 15.94%
H: 1.1%
C: -10.11%
sbp-101 patent
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101Patent developed in collaboration with Syngene International Ltd.
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 9.6%
C: 2.4%
sbp-101 patent international collaboration china
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 9.6%
C: 2.4%
sbp-101 patent
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Published: 2023-08-14 (Crawled : 12:20) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 6.79%
H: 4.05%
C: -5.2%
sbp-101 europe patent
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
Published: 2023-07-17 (Crawled : 10:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 2.88%
H: 0.0%
C: -2.8%
sbp-101 patent australia
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
Published: 2023-04-19 (Crawled : 12:20) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: -12.97%
H: 9.26%
C: -0.74%
sbp-101 association presentation cancer potential
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
Published: 2023-04-17 (Crawled : 13:00) - biospace.com/
SONN | $1.8 6.19% 5.83% 18K
|
Health Technology
|
| O: -10.05%
H: 12.76%
C: 10.2%
sb101 meeting son-1010 study
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Published: 2023-03-22 (Crawled : 14:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: -1.89%
H: 9.58%
C: 1.92%
sbp-101 patent
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
SONN | $1.8 6.19% 5.83% 18K
|
Health Technology
|
| O: 0.32%
H: 1.59%
C: -7.94%
sb101 meeting son-1010 study
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 1.68%
H: 0.66%
C: -9.75%
sbp-101 aspire trial gemcitabine pancreatic
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Published: 2023-03-01 (Crawled : 13:20) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: -13.87%
H: 1.69%
C: -14.41%
sbp-101 research association presentation cancer
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2023-01-19 (Crawled : 17:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 9.82%
H: 7.86%
C: -11.11%
sbp-101 designation ema gemcitabine pancreatic
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-12-14 (Crawled : 14:20) - globenewswire.com
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 30.91%
H: 36.67%
C: -33.78%
sbp-101 designation ema gemcitabine positive pancreatic
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-11-28 (Crawled : 16:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 5.66%
H: 0.07%
C: -10.71%
sbp-101 europe aspire trial gemcitabine pancreatic
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-09-29 (Crawled : 18:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: -2.99%
H: 6.54%
C: 3.37%
sbp-101 trial gemcitabine pancreatic
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 1.56%
H: 3.05%
C: -2.3%
sbp-101 trial gemcitabine pancreatic
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic
Published: 2022-06-28 (Crawled : 13:00) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 2.94%
H: 5.68%
C: -5.32%
sbp-101 preclinical potential cancer publication pre-clinical
Panbela Announces Poster Presentation at American Association for Cancer Research:The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer
Published: 2022-04-12 (Crawled : 13:20) - biospace.com/
PBLA | News | $0.4748 -6.31% 20K
|
Professional, Scientific, and T...
|
| O: 1.8%
H: 9.72%
C: -8.14%
sbp-101 presentation potential cancer ovarian cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.